Application of adenosine deaminase or modifier of adenosine deaminase in preparation of therapeutic drug for improving diabetes pancreas islet inflammation and protecting pancreas islet beta cell function
By systematically improving pancreatic islet immunopathology through adenosine deaminase (ADA) and its modifiers, the problem of existing drugs being unable to prevent the decline of β-cell function has been solved, resulting in reduced pancreatic islet inflammation and restoration of β-cell function, providing a novel diabetes treatment strategy.
Patent Information
- Application Number
- CN202610650466.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-05-12
- Publication Date
- 2026-07-24
AI Technical Summary
Existing hypoglycemic drugs cannot effectively prevent or reverse the persistent decline in β-cell function, and the functional significance of adenosine deaminase (ADA) in diabetes has not been fully utilized, with long-term inflammatory responses driving β-cell exhaustion.
By using adenosine deaminase (ADA) and its modifiers, through a systemic clearance-local decompression mechanism, we can systematically improve pancreatic islet immunopathology, reduce macrophages and inflammatory factors, and protect β-cell function.
It significantly reduces pancreatic islet inflammation, promotes β-cell proliferation and functional recovery, restores glucose-stimulated insulin secretion, delays diabetes progression, and provides a novel diabetes treatment strategy.